Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Venetoclax + Ibrutinib for Chronic Lymphocytic Leukemia
Recruiting1 awardPhase 2
Columbus, Ohio
This trial is testing how well venetoclax and ibrutinib work to treat people with CLL who have developed genetic mutations after being treated with ibrutinib. Venetoclax and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service